UCB Receive the US FDA’s Approval of Zilbrysq (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis
Shots:
- The US FDA has approved Zilbrysq for gMG in adult patients who are AChR Ab+. The approval was based on the P-III study (RAISE) results of Zilbrysq (SC, 0.3mg/kg) vs PBO, published in The Lancet Neurology
- The study demonstrated that Zilbrysq provides rapid, consistent & significant benefits in different patient & clinician-reported outcomes at 12wk., improvements in MG-specific efficacy outcomes & significant improvement from baseline for MG-ADL & QMG total score while other 2EPs incl. the proportion of patients with improvements of 3 & 5 points in the MG-ADL & QMG total score at 12wk. without rescue therapy
- Zilucoplan was approved in Japan for gMG in adult patients who inadequately respond to steroids or other immunosuppressants & is under review by TGA & Health Canada
Ref: PR Newswire | Image: UCB
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
